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The gut microbiota profile of adults with kidney disease and kidney stones: a
systematic review of the literature
Abstract
BACKGROUND: There is mounting evidence that individuals with kidney disease and kidney stones have
an abnormal gut microbiota composition. No studies to date have summarised the evidence to categorise
how the gut microbiota profile of these individuals may differ from controls. Synthesis of this evidence is
essential to inform future clinical trials. This systematic review aims to characterise differences of the gut
microbial community in adults with kidney disease and kidney stones, as well as to describe the
functional capacity of the gut microbiota and reporting of diet as a confounder in these studies.
METHODS: Included studies were those that investigated the gut microbial community in adults with
kidney disease or kidney stones and compared this to the profile of controls. Six scientific databases
(CINHAL, Medline, PubMed, Scopus, Web of Science and Cochrane Library), as well as selected grey
literature sources, were searched. Quality assessment was undertaken independently by three authors.
The system of evidence level criteria was employed to quantitatively evaluate the alteration of microbiota
by strictly considering the number, methodological quality and consistency of the findings. Additional
findings relating to altered functions of the gut microbiota, dietary intakes and dietary methodologies
used were qualitatively summarised. RESULTS: Twenty-five articles met the eligibility criteria and included
data from a total of 892 adults with kidney disease or kidney stones and 1400 controls. Compared to
controls, adults with kidney disease had increased abundances of several microbes including
Enterobacteriaceae, Streptococcaceae, Streptococcus and decreased abundances of Prevotellaceae,
Prevotella, Prevotella 9 and Roseburia among other taxa. Adults with kidney stones also had an altered
microbial composition with variations to Bacteroides, Lachnospiraceae NK4A136 group,
Ruminiclostridium 5 group, Dorea, Enterobacter, Christensenellaceae and its genus Christensenellaceae
R7 group. Differences in the functional potential of the microbial community between controls and adults
with kidney disease or kidney stones were also identified. Only three of the 25 articles presented dietary
data, and of these studies, only two used a valid dietary assessment method. CONCLUSIONS: The gut
microbiota profile of adults with kidney disease and kidney stones differs from controls. Future study
designs should include adequate reporting of important confounders such as dietary intake to assist with
interpretation of findings.
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The gut microbiota profile of adults with
kidney disease and kidney stones: a
systematic review of the literature
Jordan Stanford1,2*, Karen Charlton1,3, Anita Stefoska-Needham1,3, Rukayat Ibrahim4 and Kelly Lambert1,3

Abstract
Background: There is mounting evidence that individuals with kidney disease and kidney stones have an abnormal
gut microbiota composition. No studies to date have summarised the evidence to categorise how the gut
microbiota profile of these individuals may differ from controls. Synthesis of this evidence is essential to inform
future clinical trials. This systematic review aims to characterise differences of the gut microbial community in adults
with kidney disease and kidney stones, as well as to describe the functional capacity of the gut microbiota and
reporting of diet as a confounder in these studies.
Methods: Included studies were those that investigated the gut microbial community in adults with kidney disease
or kidney stones and compared this to the profile of controls. Six scientific databases (CINHAL, Medline, PubMed,
Scopus, Web of Science and Cochrane Library), as well as selected grey literature sources, were searched. Quality
assessment was undertaken independently by three authors. The system of evidence level criteria was employed to
quantitatively evaluate the alteration of microbiota by strictly considering the number, methodological quality and
consistency of the findings. Additional findings relating to altered functions of the gut microbiota, dietary intakes
and dietary methodologies used were qualitatively summarised.
Results: Twenty-five articles met the eligibility criteria and included data from a total of 892 adults with kidney
disease or kidney stones and 1400 controls. Compared to controls, adults with kidney disease had increased
abundances of several microbes including Enterobacteriaceae, Streptococcaceae, Streptococcus and decreased
abundances of Prevotellaceae, Prevotella, Prevotella 9 and Roseburia among other taxa. Adults with kidney stones also
had an altered microbial composition with variations to Bacteroides, Lachnospiraceae NK4A136 group,
Ruminiclostridium 5 group, Dorea, Enterobacter, Christensenellaceae and its genus Christensenellaceae R7 group.
Differences in the functional potential of the microbial community between controls and adults with kidney disease
or kidney stones were also identified. Only three of the 25 articles presented dietary data, and of these studies, only
two used a valid dietary assessment method.
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Conclusions: The gut microbiota profile of adults with kidney disease and kidney stones differs from controls.
Future study designs should include adequate reporting of important confounders such as dietary intake to assist
with interpretation of findings.
Keywords: Gastrointestinal microbiome, Kidney diseases, Nephrolithiasis, Systematic review, Diet therapy

Background
The link between the gut microbiome and human diseases continues to emerge in recent literature and has
become a focus for global scientific endeavours to mitigate kidney disease development and progression [1].
The human microbiome is a complex ecosystem comprising of all the genetic material inside the trillions of
microorganisms that live within and on us. Whereas, the
microbiota is the community of micro-organisms found
in a particular sample or location, which includes bacteria, bacteriophage, viruses, fungi, and protozoa [2, 3].
Advancements in microbial characterisation methods
have facilitated our understanding of the complex mechanistic links between the microbiome and disease. There
are numerous methods to categorise gut microbial composition and measure diversity. For instance, some
methods are based on sequence divergences of the small
subunit ribosomal RNA (16S rRNA) [4, 5], which provide helpful insights into the diversity of the gut microbiota, as well as qualitative and quantitative information
based on what microbes are present. Examples of this
technique include fluorescence in situ hybridization
(FISH), DNA microarrays, and next-generation sequencing of the 16S rRNA gene or its amplicons [5]. Metagenomic or shotgun sequencing is another type of analysis
which randomly sequences all extracted DNA in a given
sample. This technique offers a higher taxonomic resolution by allowing the identification of microbial taxa
present in a community at the species and strain level,
in addition to providing information on the functional
potential of the microbial community [4–6].
The microbiota encompasses far more metabolic genes
than that of the human genome [2] and offers humans
with additional unique functional capabilities via specific
enzymes and metabolic pathways. Typically, these microbes have a harmonious relationship with their host
[7] and contribute to several functional activities including micronutrient and immune homeostasis, energy metabolism, and host defences against pathogens [2, 8, 9].
However, in individuals with chronic kidney disease
(CKD), evidence suggests that a microbial imbalance
(dysbiosis) leads to an increase in harmful nephrovascular uraemic toxins [10–13]. The retention of these uraemic toxins, particularly indoxyl sulphate (IS), p-Cresyl
sulphate (pCS), phenylacetylglutamine (PAG) and trimethylamine N-oxide (TMAO) have been associated

with adverse complications, all of which negatively impact on the quality of life for individuals living with kidney
disease. These complications include accelerated disease
progression [14, 15], increased risk of cardiovascularrelated mortality [15–17] and common symptoms such as
constipation and cognitive decline [18]. Currently, the
only known mechanism for reducing uraemic toxins in
CKD is dialysis. Nevertheless, existing evidence indicates
that only the free fraction of the protein-bound toxins
pCS and IS can diffuse across the dialysis membrane,
resulting in a limited capacity for removal [11]. Therefore,
the development of novel strategies (other than dialysis)
to reduce the production of major uraemic toxins, particularly in the earlier stages of CKD, is warranted.
The role of the gut microbiota in kidney stone disease
historically focused on the presence of Oxalobacter formigeme [19], a gram-negative bacterium with the functional ability to degrade oxalate. Thus, a deficiency of
Oxalobacter formigene present in stool samples was previously assumed to be a risk factor for kidney stone disease [20–22]. However, clinical studies provided
questionable results, as Oxalobacter formigene has also
been isolated from samples of recurrent stone formers
[23, 24]. Since advancements in culture-independent
methods for gut microbiota investigations that have become more available in the last decade [5], studies have
made attempts to evaluate the relationship between gut
microbiota and kidney stone formation in more comprehensive ways, shedding new light on the gut-kidney axis
in nephrolithiasis.
Diet forms a critical component in the overall medical
strategy for kidney disease and plays a fundamental role
in determining the composition and functional activity
of the human gut microbiota [25], with implications for
uraemic toxin production [11, 13, 26–28]. Moreover,
diet-based approaches such as ensuring adequate intake
of fluid and dietary calcium, while avoiding high intakes
of sodium and animal protein are crucial nonpharmacological prevention strategies for kidney stone
disease. Therefore, dietary interventions and targeted
nutritional therapies offer a potential approach to
microbiota-associated diseases and mitigate uraemic
toxin generation and kidney stone formation. Investigations into how the gut microbiota differs with disease
and lifestyle factors such as diet will enhance not only
our understandings of the contribution these microbes
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have in host biology but also understandings of the complicated exchange between diet and disease.
Differences in the composition of the gut microbiota
in kidney disease and kidney stone populations compared to controls remains unclear due to the lack of a
quantitative overview of existing evidence. The investigation into how the microbial signatures of adults with
kidney disease or kidney stones may deviate from controls
is essential to inform future trials. Hence, this review aims
to systematically characterise the gut microbial composition in adults with kidney disease or kidney stones compared to controls and gain a better understanding of the
functional capacity of the microbiota and reporting of diet
as a confounder in these studies.

Methods
Protocol

The systematic literature review was reported following
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [29] and registered at
PROSPERO (No. CRD42018109173, http://www.crd.york.
ac.uk/).
Article selection

The inclusion criteria were as follows:
(1) Original research that examined the gut microbial
community from adults with kidney disease or
kidney stones and compared that to controls. This
encompassed studies which reported to include
adults with CKD; end-stage kidney disease (ESKD);
glomerulonephritis; nephrotic syndrome; IgA
nephropathy (IgAN); polycystic kidney disease;
diabetic nephropathy (DN); Alport syndrome; Fabry
disease; individuals who are receiving renal
replacement therapies such as haemodialysis
(HD), peritoneal dialysis (PD), kidney transplant
(KT); or adults with kidney stones (any stone
type).
(2) Studies reporting on the microbial community from
stool or intestinal biopsy samples;
(3) Full-text articles available in English.
Studies for exclusion were:
(1) Animal or in-vitro studies, case reports, abstracts,
commentaries, review articles, editorials, expert
opinion, letters, guidelines, protocols, seminars,
reports, books or book chapters;
(2) Study populations which included children;
(3) Study populations which included adults with acute
conditions (haemolytic uremic syndrome, acute
kidney injury or urinary tract infections), renal
cancer, kidney-yin deficiency syndrome or stones
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which were reported in other sites, such as the ureter or urethra.
Search strategy and study selection

Six scientific databases including CINHAL, Medline,
PubMed, Scopus, Web of Science and Cochrane Library
as well as grey literature sources: Trove, the National Kidney Foundation Website, Google Scholar, Google.com.au,
National Institute for Clinical Excellence (NICE) and TRIP
Medical Database, were searched up until 7th August
2018. A research librarian was consulted to refine search
terms and selection of databases. Reference lists of manuscripts were also scanned to discover additional relevant
articles. A full-updated search using the original search
strategy was undertaken on the 3rd October 2019 using
the same six scientific databases as well as Google Scholar.
The search strategy for all databases can be found in Item
1 of this manuscript’s supplementary information (Additional file 1). All citations were imported by one member
of the research team in Endnote (Endnote X8, Thomson
Reuters, 2016) for review.
Two reviewers [JS, RI] independently screened the titles,
abstracts and full texts for inclusion in this review. Discrepancies were resolved by consensus or adjudication by
other members of the research team [KC, KL]. At the
stage of full-text review, the decision to restrict articles to
only those that included at least one of the following
methods was made: Metagenomic sequencing (shotgun
sequencing), amplicon-based sequencing methods including 16S rRNA sequencing, quantitative real-time polymerase chain reaction (qPCR) sequencing, DNA microarray
or fluorescence in situ hybridization (FISH) techniques.
These methods are culture-independent methods that enable phylogenetic identification and quantification, which
will help to provide novel insights into the composition
and/or diversity of the microbiota.
Summary measures

The overall microbiota structure (α-diversity and βdiversity) and differences in the abundance of microbes
at specific taxonomic levels (phylum, order, class, family,
genus, species, OTU) were the primary outcomes of this
paper. The secondary outcomes were descriptions of the
real or predicted functional capacity of the microbiota,
details on dietary intake and the dietary assessment
methods used in each study.
Data extraction and quality assessment

Relevant data in all eligible studies were extracted into
an excel spreadsheet by one investigator, and another
member of the research team cross-checked 25% of the
input. Only statistically significant results (p < 0.05) that
reported compositional differences of the gut microbiota
between the groups of interest compared to controls, at
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each taxonomic level, were imported into excel. Additional information was also extracted: country of study,
demographics (age, gender, and ethnicity), sample collection and storage methods, description of antibiotic
and medication use, type of taxonomic database used,
microbial characterisation method, microbial diversity
metrics, and dietary methods.
To assess the quality of studies, three independent reviewers [JS, KL, ASN] used the Newcastle-Ottawa Scale
(NOS) [30]. Appraisal items in the NOS tool were
grouped into three categories: the selection of the study
groups; the comparability of the groups; and the ascertainment of the exposure (the collection and assessment
of samples for microbial communities) as the outcome
of interest [30]. Overall, studies which scored seven or
above using the NOS tool was considered to be of ‘highquality’ [30–32].
Data synthesis

Due to the heterogeneity of study methods and the absence of raw sequencing data, it was not possible to undertake a meta-analysis. Instead, a quantitative assessment of
the microbial composition was performed. The quantitative approach applied the system of evidence level criteria
(Table 1), according to a ranking-based system documented elsewhere [33–35]. Benefits of this approach are
that it considers the number and methodological quality of
included studies, as well as the consistency of reported
findings. Study findings were deemed highly consistent
and graded as ‘strong evidence’ when 75% or more of the
studies that reported a particular bacteria were in agreement, whereby the same trend in microbial alteration (increased or decreased) relative to controls was found in at
least two high-quality studies as determined by the NOS
quality score. Finally, data on the functional potential of the
microbial community, dietary intakes and dietary assessment methodologies used were qualitatively summarised.

Results
Summary of included studies

The original literature search yielded 4155 articles, of
which 110 full-text articles were evaluated. The updated
Table 1 The system of evidence level criteria
Grading

Criteria

Strong

Consistent findings (≥75%) in at least 2
high-quality studies

Moderate

Consistent findings (≥75%) in one high-quality
study and at least one low-quality study

Weak

Findings of one high-quality study or consistent
findings (≥75%) in at least 3 or more low-quality
studies

Inconclusive

Inconsistent findings, or consistent findings
(≥75%) reported in less than 3 low-quality studies
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search provided an additional 1388 papers, of which nine
full-text articles were suitable for inclusion. A total of 25
articles met the eligibility criteria (Fig. 1). All 25 papers
reported cross-sectional data on 722 adults with kidney disease, 170 adults with kidney stones and 1400
control participants (Table 2). Only different results
obtained from the papers using the same study populations [36–38, 48] were extracted to avoid duplication.
Majority of articles reported on adults with CKD who
were not receiving a renal replacement therapy, including studies that exclusively investigated IgAN [39] and
DN cohorts [40, 41] (Table 2, n = 10). Three papers investigated adults undertaking HD, and another study included individuals receiving PD therapy. Five additional
articles included mixed kidney disease cohorts within
their sample. No studies reported to exclusively investigate the gut microbiota profile in individuals with glomerulonephritis, nephrotic syndrome, polycystic kidney
disease, Alport syndrome, Fabry disease, and compared
that to a control group. The remaining six articles investigated adults with kidney stones. The age structure of
cohorts did vary; although there was some overlap across
studies, including a mean sample population age between 41 and 64.5 years. The portion of males ranged
from 22 to 100%. Overall, studies were predominately
from China (n = 12/25), followed by the United States of
America (n = 3/25) and Italy (n = 2/25).
All eligible studies used stools samples for their gut
microbiota analysis. Eighteen articles reported using frozen stool samples for their analysis, where storage temperatures ranged from − 20 °C to − 80 °C. Others reported
that samples were processed within 24 h of receipt [42] or
kept on ice and processed within 1 h of defecation [43].
The remaining articles failed to provide sufficient details
regarding the storage and processing methods utilised [36,
44–46, 48]. Four articles assessed the gut microbiota using
only qPCR [41, 43, 47, 49]. The remaining studies assessed
gut microbiota via high-throughput molecular approaches:
Illumina platforms (MiSeq, NextSeq, HiSeq), Iron Torrent
PGM system or bTEFAP using 454 FLX sequencer, DNA
microarray analysis performed using PhyloChip assay.
However, three papers did not report the sequencing platform used [44, 45, 55]. Among these studies, four
employed a combination of microbial characterisation
techniques in addition to 16S rRNA sequencing, including: shotgun sequencing [50]; qPCR [38, 37, 51]; denaturing gradient gel electrophoresis (DGGE) fingerprinting
[38] as well as gene-targeted amplicon sequencing of functional genes involved in oxalate and butyrate metabolism
(frc- [37, 38], but- and buk- gene [37]). Two research
groups also utilised fungal specific primers for their qPCR
analysis [41], as well as 18S rRNA and fungal ITS1 region
primers for amplicon sequencing [37] to explore members
of the microbial communities other than just bacteria.
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Fig. 1 PRISMA flow diagram

Risk of bias and heterogeneity

Using the Newcastle-Ottawa Scale, of the 25 final articles, 11 were considered high-quality with a score of
seven or above (Table 3). There were multiple sources of
heterogeneity among studies, including: the collection,
handling and storage temperature of samples, DNA extraction method, the primer used for PCR, the variable
region of the conserved genes (for instance the 16S
rRNA gene) and the sequencing platform used. Also,
some methods employed cannot evaluate the whole microbial community, such as qPCR, which can only detect
selected microbes. Moreover, although there were some
consistencies, many papers differed with their statistically analysis and presentation of the gut microbial data.
A few articles were also not consistent in reporting the
CKD stage of their participants or details of the diagnostic
criteria used for the classification of CKD. Other sources
of heterogeneity included the age, gender, ethnicity

of participants and the recruitment of controls. For instance, one study only recruited males [38], while seven of
the eight papers that reported ethnicity recruited one ethnic group: Chinese [40, 47, 51–53, 56] or Caucasian [39].
Details relating to the recruitment of control groups were
often missing or differed across studies, with some articles
reporting that their controls were hospital or clinic staff.
Furthermore, the classification of ‘controls’, the timing of
antibiotic usage before study participation, reporting of
medications and other co-existing conditions was not consistent across studies and more often poorly defined.
Microbial diversity and richness

Alpha (α) diversity is the measure of the number (richness)
and distribution (evenness) of taxa within a sample [54].
Sixteen articles reported results for α-diversity, of which five
observed no significant difference between groups [38, 45,
48, 51, 53]. Eight articles reported that α-diversity was

Country

Demographics
of patients

Demographics
of controls

N = 24
recurrent
calcium oxalate
stones.
Age: 22-50yrs,
100% male;
ethnicity not
reported.

India

Suryavanshi
2016 [38]

N = 23; all
stone types
included
Age: 53.7 ±
15.4yrs, 22%
male; 13%
African
American, 35%
Hispanic, 52%
Caucasian.

N = 13; stone
types not
reported.
Age: 52.25 ±
7.25yrs, 38%
male; 100%
Chinese.

USA

Stern 2016
[58]

N = 52
recurrent
idiopathic
calcium stones
Age: 48 ±
11yrs, 60%
male; ethnicity
not reported

Tang 2018 [53] China

Italy

Ticinesi 2018
[50]

N = 15
Age: 22-52yrs,
100% male;
ethnicity not
reported.

N = 13
Age: 55.81 ±
5.79yrs,
38% male;
100% Chinese.

N=6
Age: 53.5 ±
16.0yrs, 67%
male; 50%
African
American and
50% Caucasian.

N = 48
Age: 47 ±
13yrs, 58%
male; ethnicity
not reported.

ADULTS WITH KIDNEY STONES (n= 6 articles)

Reference

Table 2 Characteristics of included studies

Self-sampled;
Stored -80°C

Excluded if
taken in
prior 3
months.

Control
group did
not have
antibiotics in
prior 3
months;
unclear if
this was the
same for
kidney stone
group.

Excluded if
taken in
prior 2
weeks.

Self-sampled;
Flash-frozen
with dry ice
& stored
-80°C

Self-sampled;
Immediately
frozen &
stored -80°C.
(DNA
samples
stored at
-20°C)

Excluded if
taken in
prior 30
days.

Antibiotic
use

Self-sampled;
Delivered to
clinic within
2 hours from
collection
and stored at
-22°C;
Processed ≤
2 weeks of
receipt

Stool
collection,
temp. &
storage

Greengenes

SILVA (16S
rRNA), whole
NCBI nr
(shotgun)

Taxonomy
database

Not reported

Greengenes
(16S rRNA) &
M5NR
database
(frc-gene)

None of the adults
RDP
with kidney stones
were reported to be
on any medications
before sample
collection.

Not reported

Not reported

Medications

Not reported

Reported number of
participants who
follow a vegetarian
diet; dietary intake
results and
assessment methods
not reported.

α-diversity reported
not significantly
different (Chao1,
Shannon, Simpson’s
and Good’s coverage
indices, p>0.05)
Overall, β-diversity was
distinct but not
significantly different
(p=0.096 with ANOSIM
and p=0.058 with
MPRR based on BrayCurtis distance metric)
α-diversity reported
not significantly
different (Chao1,
observed species/OTUs,
phylogenetic diversity,
Shannon and
Simpson’s indices)
β-diversity metrics
reported to reveal
compositional

16S ribosomal
RNA amplicon
sequencing
(V4 region)
Illumina Hiseq
2500 platform

16S ribosomal
RNA gene and
frc-gene
amplicon
sequencing;
quantitative
polymerase chain
reaction & PCRDGGE
(V3 region of 16S

EPIC FFQ delivered by
a nutritionist; Calcium
intake lower in adults
with KS (p<0.04).
Calcium intake
considered as a
covariate in the
analysis of gut
microbiota data.

Dietary assessment

Not reported

↓ α-diversity in KS
group vs. controls
(Chao1 index; p<0.05);
β-diversity significantly
different between
groups (p=0.002 with
PERMANOVA and p=
0.004 with Adonis test
based on Bray-Curtis
and weighted UniFrac
metrics)

Diversity metrics

Not reported

16S ribosomal
RNA gene
sequencing
(V4 region)
Illumina MiSeq

16S ribosomal
RNA gene
sequencing
(V3 region)
Illumina MiSeq &
shotgun
metagenomics
on sub-sample
(n=10)
Illumina NextSeq

Microbiota
analysis
technique

Stanford et al. BMC Nephrology
(2020) 21:215
Page 6 of 23

Iran

Tavasoli 2019
[49]

N = 58
(majority
confirmed to
have calcium
stones)
n = 29
recurrent
stones with
hyperoxaluria
Age: 44.21 ±
9.58yrs,
62.1% male.
n = 29
recurrent
stones without
hyperoxaluria
Age: 48.07 ±
9.20yrs, 72.4%
male.
Ethnicity not
reported

Same as the
population
above
N = 24
recurrent
calcium oxalate
stones.
Age: 22-50yrs,
100% male;
ethnicity not
reported.

Demographics
of patients

Al-Obaide
2017 [42]

USA

N = 20 CKD*
N = 20
(CKD stage not Age:54.3±

Self-sampled;
Processed

Excluded if
taken for

Individuals not reported to be undertaking a renal replacement therapy (n=10)

Self-sampled;
stored -20°C

Greengenes

Taxonomy
database

Participants of the
T2DM-CKD group

Curated
database

Medications not
N/A
reported; individuals
excluded from the
study if taking
calcium,
magnesium,
potassium or
pyridoxine
supplementation.

Excluded if
taken in
prior 2
months.

Medications

N = 29
Age: 41.42 ±
11.48yrs,
89.7 % male;
ethnicity not
reported.

Antibiotic
use

Not reported Not reported

Stool
collection,
temp. &
storage

N = 48
Not reported
(Additional n =
33 controls
recruited).
Age and
gender only
reported for a
subset of n =
15 (as above);
ethnicity not
reported.

Demographics
of controls

Diversity metrics

α-diversity investigated
in selected sub-sample
(n = 7 KSD, n = 7
controls); authors
reported significant
decrease observed in
KSD group (Chao1,
Shannon and
Simpson’s indices; pvalue not reported).
β-diversity not
reported.

16S ribosomal
RNA gene

Not reported.

Real-time
N/A
polymerase chain
reaction

Targeted
sequencing (frc-,
but- and buk-,
16S and 18S
ribosomal RNA
genes as well as
fungal ITS1
region) &
quantitative
polymerase chain
reaction
Iron Torrent PGM
system

differences between
rRNA gene)
Iron Torrent PGM groups (PCoA plots of
system
weighted and
unweighted UniFrac
results; statistical test
and p-value not
reported).

Microbiota
analysis
technique

Dietary assessment
methods not stated.

Not reported

Not reported

Dietary assessment

(2020) 21:215

ADULTS WITH KIDNEY DISEASE (n =19 articles)

India

Country

Suryavanshi
2018 [37]

Reference

Table 2 Characteristics of included studies (Continued)
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China

Jiang 2016
[47]

Excluded if
taken in
prior 3
months.

Excluded if
taken in
prior 4
weeks.

N = 16
Self-sampled;
eGFR: 96 ± 7;
Stored -80°C
Age: 43 ± 8yrs,
60% male.
100%
Caucasian

Self-sampled;
N = 20
eGFR: 104.99 ± Stored at
19.82; Age:
-80°C
43.05 ±

Data on
antibiotics
usage was
collected for
the prior
month; data
available for
only 11% of
study
participants.

atleast 3
consecutive
days in the
prior month

≤24hrs of
receipt

Self-sampled;
Refrigerated
up to 2 days
prior to clinic
visit; Stored
at -80°C

Antibiotic
use

Stool
collection,
temp. &
storage

Taxonomy
database

Microbiota
analysis
technique

Greengenes

Not reported

N/A

All IgAN participants RDP
treated with ACEi.
Other medications
undefined; no
remarkable changes
reported to
medications in prior
month.

Not reported

Reported no
remarkable changes
to participant’s diet in
prior month. Dietary
assessment method
or results not
reported.

↓ α-diversity in IgAN
group vs. controls
(Chao1, observed
species/OTUs and
Shannon indices; p<
0.05)
β-diversity not
reported.

Not reported

Dietary scores were
obtained from EPIC
FFQ generated
through PCA. Diet
scores were
considered as
covariates in the linear
mixed effects
regression models; no
significant results
reported.

Macronutrient data
presented as a
percentage of total
energy intake; protein
intake higher in
controls (p<0.05) and
fat intake higher in
CKD group (p<0.01)

Dietary assessment

Not reported

Diversity metrics

Quantitative
N/A
polymerase chain
reaction

Bacterial tagencoded FLXtitanium
amplicon
pyrosequencing
bTEFTAP
(V1-V3 region)
454 FLX
Sequencer

16S ribosomal
RNA gene
sequencing
(V4 region)
Illumina MiSeq

treated with insulin, from
sequencing
OHAs, ranitidine, PPI, Greengenes, (V3-V4 region)
ACEi, ARBs, statin
RDPII & NCBI Illumina MiSeq
therapy

Medications

(2020) 21:215

N = 65 (CKD
stage 1-5 )
eGFR: 55.61 ±
52.55;

N = 32 IgAN
(CKD stage not
reported)
n = 16 nonprogressors,
eGFR: 76 ± 15;
Age: 41 ±
10yrs, 69%
males.
n=16
progressors,
eGFR: 30±18;
Age:45 ± 6 yrs,
63% male.
100%
Caucasian.

Italy

De Angelis
2014 [39]

3.2yrs;
eGFR, gender
and ethnicity
not reported.

reported, all
were reported
to have T2DM)
eGFR: 16.54 ±
3.01; Age: 64.4
± 2.3yrs.
Gender and
ethnicity not
reported.
*Stool samples
of n=18/20
were analysed
to identify the
gut microbial
profile
N = 793
eGFR >60;
Age, gender
and ethnicity
not reported
for sub-sample.

Demographics
of controls

Demographics
of patients

N = 62 (CKD
stage not
reported).
eGFR: reported
≤60;
Age, gender
and ethnicity
not reported
for sub-sample.

Country

Barrios 2015 UK
[61]

Reference

Table 2 Characteristics of included studies (Continued)

Stanford et al. BMC Nephrology
Page 8 of 23

N = 52 (CKD
stage 5)
eGFR: 6.86 ±
2.87;
Age: 51.58 ±
18.33yrs, 56%
male. 100%
Han Chinese
nationality.

China

Romania N = 9 DN (CKD
stage not
reported)
eGFR, age,
gender and
ethnicity not
reported .

China

Jiang 2017
[51]

Gradisteanu
2019 [41]

Tao 2019
[40]

N=5
eGFR, age,
gender and
ethnicity not
reported.

N = 60
eGFR: 98.03 ±
27.32; Age:
52.53 ±
13.98yrs, 42 %
male. 100%
Han nationally
Chinese

N = 10
Age: 55 (4167yrs) yrs, 50%
male. eGFR
and ethnicity
not reported.

Self-sampled;
Stored at
-20°C

Self-sampled;
Stored at
-80°C

Not reported

Sample
collection
method
unclear;
Stored at
-40°C

Stool
collection,
temp. &
storage

Excluded if
taken in the

Not reported

Microbiota
analysis
technique

SILVA

SILVA

N/A

16S ribosomal
RNA gene

Not reported

Dietary assessment

↑ α-diversity richness
DN vs. T2DM controls

Excluded if following
restrictive diets.

Not reported

α-diversity reported
Not reported
not significantly
different (Chao1,
observed species/OTUs,
Shannon and
Simpson’s indices).
No difference in βdiversity reported
between groups (PCoA
plot based on UniFrac
metric, statistical test or
p-value not reported).

↑ α-diversity ESKD vs.
Not reported
controls (observed
species/OTUs index; p=
0.017).
β-diversity not
reported.

↓ α-diversity in CKD
group vs. controls
(phylogenetic diversity
and Shannon indices;
p<0.001)
β-diversity significantly
different between
groups (ADONIS
analysis based on
unweighted UniFrac
metric, p<0.001)

Diversity metrics

Real-time
N/A
polymerase chain
reaction
(Bacterial and
fungal groupspecific primers
were also used)

Quantitative
polymerase chain
reaction
&
16S ribosomal
RNA gene
pyrosequencing
in sub-sample
(n = 27 ESKD
and n = 26
controls)
(V4-V6 region)
Illumina GAII

16S ribosomal
RNA gene
pyrosequencing
(V1-V3 region)
Sequencing
platform not
reported

Not reported 16S rDNA and
rRNA sequencing
(V4 region)
Illumina MiSeq

Taxonomy
database

ESKD participants
Not reported
treated with
phosphate
binders, antihypertensives and
various vitamin and/
or mineral
supplementation
(iron, calcium and
vitamin D)

Medications not
reported;
Corticosteroids,
statins, or cytotoxic
drugs were not
taken in the prior 3
weeks.

Not reported

Medications

Not reported Not reported

Excluded if
taken in
prior 4
weeks.

Excluded if
taken in
prior 3
weeks.

Excluded if
taken in the
prior month.

Antibiotic
use

(2020) 21:215

N = 14 DN
N = 28
Self-sampled;
(CKD stage not n = 14 healthy stored at

N = 30
(reported
ESKD)
Age: 54 (37-71)
yrs, 53% male.
eGFR and
ethnicity not
reported.

China

Wang 2012
[44]

N = 32
eGFR: reported
≥90; Age:
55.03 ±
10.38yrs,
50% male;
100% Chinese

9.88yrs,
30% male.
100% Chinese

Age: 43.45 ±
16.90 yrs, 46%
male. 100%
Chinese

N = 32 (CKD
stages 4-5)
eGFR: reported
<30; Age: 53.34
± 14.47yrs, 50%
male; 100%
Chinese

Demographics
of controls

Demographics
of patients

China

Country

Xu 2017
[56]

Reference

Table 2 Characteristics of included studies (Continued)
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China

Country

N = 22
eGFR: 97.06 ±
12.98;
Age:50.27 ±
7.77yrs, 55%
male. 100%
Chinese

controls
eGFR: 96.01 ±
9.29; Age:
52.86 ±
9.91yrs, 64%
male.
n = 14 T2DM
controls
without CKD
eGFR: 93.48±
13.02; Age:
53.29yrs ±
9yrs, 64%
male.
100% Chinese.

reported)
eGFR: 93.26 ±
17.0;
Age:52.93 ±
9.98 yrs, 64%
male. 100%
Chinese.

N = 50 (CKD
stage not
reported)
eGFR: 22.39 ±
15.56;
Age:52.4 ±
13.49yrs, 54%
male. 100%
Chinese.

Demographics
of controls

Demographics
of patients

Self-sampled;
transported
on ice and
stored at
-80°C

-80°C

Stool
collection,
temp. &
storage

Excluded
taken in
prior 3
months.

prior 30
days.

Antibiotic
use

USA
Vaziri 2013
[48] & Wong
2014 [36]

N = 24
eGFR not
reported.
Dialysis
vintage: ≥3
months, Kt/V =
1.5 ± 0.3.
Age: 57 ± 14
yrs, 25% male.
38% Caucasian,
54% Hispanic,
and 8% Asian.
N = 12
Not reported
eGFR not
reported.
Age: 51 ± 12
yrs,
33% male.
33% Caucasian,
58% Hispanic,
and 8% Asian.
Excluded if
taken in
prior 3
months.

Individuals undertaking a renal replacement therapy: Haemodialysis (n=3 articles)

Li 2019 [52]

Reference

Table 2 Characteristics of included studies (Continued)

HD patients were
treated with
phosphate binders,
ESAs (Darbopoetin),
vitamin & mineral
supplementation.
Immunosuppressive
drugs not to be
taken in prior 3
months.

Medications not
reported;
Immunosuppressive
drugs not to be
taken in prior 3
months.

Medications

Greengenes
(Wong)

RDP

Taxonomy
database

Microarray
sequencing; 16S
ribosomal RNA
gene PhyloChip
analysis

16S ribosomal
RNA gene
pyrosequencing
(V3-V4 region)
Illumina HiSeq

pyrosequencing
(V3-V4 region)
Illumina MiSeq

Microbiota
analysis
technique

Strict fluid and dietary
sodium, phosphorus,
and potassium
restrictions; Nutrition
prescription,
education or
counselling methods
and results not
reported.

Not reported

↓ α-diversity in CKD
group vs. controls
(Phylogenic diversity
whole-tree index), p<
0.05, and reduced but
not significant for
Shannon or Simpson’s
indices p> 0.05).
β-diversity significantly
different between
groups (ANOSIM test
based on unweighted
UniFrac, p= 0.001)

Relative richness
(assessed for
subfamilies at
subphylum level) was
reported to be similar
between groups (pvalue not reported).
β-diversity revealed
tighter clustering in the
control group than HD
group (NMDS figure
based on Bray-Curtis
distance metric;
statistical test or pvalue not reported)

Reported similar/same
eating habits across
some of their groups;
however, no formal
dietary assessment
was undertaken.

Dietary assessment

(observed species/
OTUs index, p= 0.023;
but no difference
found for other αdiversity indices)
β-diversity significantly
different between
groups (PERMANOVA
based on Bray-Curtis
metric, p = 0.02).

Diversity metrics

Stanford et al. BMC Nephrology
(2020) 21:215
Page 10 of 23

China

Country

N = 21
Dialysis
vintage: ≥3
months, spKt/V
reported >1.2
and regularly
monitored.
Age: 53.0 ±
9.0yrs, 57%
male.
eGFR and
ethnicity not
reported.

Demographics
of patients

N = 20 (Unit
staff)
Age:31 ±
9.1yrs, 50%
males.
eGFR and
ethnicity not
reported.

Demographics
of controls

Self-sampled;
storage not
reported.

Stool
collection,
temp. &
storage

Taiwan

N = 29
eGFR: reported
<15;
Dialysis
vintage: 49.7 ±
35.4 months,
Kt/V not
reported; Age:
53.7 ± 11.7yrs,
34% male.
Ethnicity not
reported.
N = 41
Age: 58.2 ±
12.8yrs, 37%
male.
eGFR and
ethnicity not
reported.
Self-sampled;
Immediately
put on ice;
Processed
≤1hr of
defecation
Excluded if
taken in
prior 30
days.

Not reported

N/A

RDP, BLAST

Taxonomy
database

Diet reported being
‘controlled for’,
although methods
and results were not
reported.

α-diversity not
significantly different
(Shannon index; p=
0.429).
β-diversity not
reported.

Shi 2014
[55]

China

N = 52
n = 22 HD
group
Dialysis
vintage: 6-40
months, Kt/V
not reported.
n = 30
reported ESKD
not
undertaking
dialysis.
eGFR, age,
gender and
ethnicity not
reported.
N = 10
eGFR, age,
gender and
ethnicity not
reported.
Details of
sample
collection not
reported;
Samples
immersed in
90% alcohol
and stored at
-20°C
Excluded if
taken in
prior 3
weeks.

Medications not
reported;
Corticosteroids,
statins, cytotoxic
drugs not taken in
prior 3 weeks.

SILVA

16S ribosomal
RNA gene
Pyrosequencing
(V1-V3 region)
Sequencing
platform not
reported

↑ α-diversity in HD
Not reported
group vs. controls
(average OTUs/ species,
p=0.044) and Chao1
index higher in three
HD samples (p-value
not reported).
β-diversity not
reported between
study groups. However,
PCA plot of Unifrac
data from selected
samples at the genus
level exhibited a large
separation in the same
three HD samples vs.
the other selected
samples (p-value or

Not reported

Dietary assessment

Diversity metrics

Real-time
N/A
polymerase chain
reaction

16S ribosomal
RNA gene
pyrosequencing
(V1-V3 region)
Sequencing
platform not
reported

Microbiota
analysis
technique

Mixed cohorts of individuals with chronic and end-stage kidney disease including those undertaking different renal replacement therapies (n= 5 articles)

Wang 2012
[43]

Medications

Not reported Medications at
baseline not
reported; HD
patients had not
taken lanthanum
carbonate in prior 3
months.

Antibiotic
use

Individuals undertaking a renal replacement therapy: Peritoneal dialysis (n=1 article)

Miao 2018
[45]

Reference

Table 2 Characteristics of included studies (Continued)
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Austria

China

China

Lun 2019
[60]

Li 2019 [62]

Country

Stadlbauer
2017 [57]

Reference

N = 53
n = 29 HD
group
eGFR: 5.75
(4.35–8.26);
Dialysis vintage
and Kt/V not
reported.

N = 49 (n =13
treated with
HD)
Age: 54 ±14
yrs, 76% male;
eGFRand
ethnicity not
reported.

N = 30
n = 15 PD
group
GFR (ml/min):
7.9 (7.3; 14.0);
Dialysis
vintage: 25 (1574) months.
Age: 62yrs (5469), 80% male.
n = 15 HD
group
GFR (ml/min):
6.0 (5.9; 9.3);
Dialysis
vintage: 70 (40197) months,
Kt/V not
reported.
Age: 61yrs (5471), 67% male;
Ethnicity not
reported.

Demographics
of patients

Self-sampled;
Stored at
-80°C

Stool
collection,
temp. &
storage

N = 69
eGFR: 126.07
(102.80–
148.65);
Age: 51yrs
(39.5-64), 39 %
male.
Ethnicity not
Collected in
sterile 2mL
tube on ice,
containing
pure ethanol
and frozen
within 30
minutes;

N = 24
Self-sampled;
Age: 56 ± 9
Stored at
yrs, 67% males; -80°C
eGFR and
ethnicity not
reported.

N = 21
GFR (ml/min):
77.6 (73.4;
86.6).
Age: 58 yrs
(53-62),
43% male.
Ethnicity not
reported.

Demographics
of controls

Table 2 Characteristics of included studies (Continued)
Medications

Excluded if
taken in
prior 4
weeks.

Excluded
taken in
prior 3
months.

HD and CKD
participants were
treated with
phosphate binders.
Medication history
of the last month
was collected, but
results were not

Not reported

Not reported Participants from
HD and PD groups
treated with
phosphate binders,
PPI,
immunosuppressive
drugs. Small
number of controls
(n=2) also treated
with PPI.

Antibiotic
use

16S ribosomal
RNA gene
sequencing
(V1-V2 region)
Illumina MiSeq

Microbiota
analysis
technique

Greengenes

16S ribosomal
RNA gene
sequencing
(V1-V2 region)
Illumina HiSeq
2500 system

Not reported 16S ribosomal
RNA gene
sequencing
(V3-V4 region)
Illumina HiSeq
(PE250)

SILVA

Taxonomy
database

Dietary assessment

↓ α-diversity in CKD
and HD group vs.
controls (Chao1, ACE
and Shannon indices
p<0.001).
β-diversity reported
being different
between groups (PCoA

Reported similar
eating habits across
the cohort, although
methods and results
were not reported.

α-diversity not
Not reported
reported.
β-diversity reported
being distinct between
CKD vs. controls;
unclear if statistically
significant (PCA plot
based on the Euclidean
distance & NMDS
based on the UniFrac
distance metric;
statistical test or pvalue not reported)

↓ α-diversity in PD and Not reported
HD group compared to
controls (Chao1 index,
p<0.05, similar results
reported for observed
species/OTUs and
phylogenic diversity)
β-diversity significantly
different between HD
vs. controls p=0.012
and PD vs. controls p=
0.003 (ANOSIM test
based on Bray Curtis,
weighted and
unweighted UniFrac
metrics)

statistical test not
report).

Diversity metrics
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China

Country

Demographics
of controls

N = 100
n = 16 KT
recipients
(sampling
reported
within the first
month after
transplantation)
Age: 42.8±
11.5yrs.
n = 84 CKD
group (stage 34)
Age: 55.9±18.2
yrs.
eGFR, gender
and ethnicity
not reported.
N = 53
Age: 54.7 ±
12.8yrs; eGFR,
gender and
ethnicity not
reported.

Age: 54yrs
explicitly
(41.5-69), 59% reported.
male.
n = 24 ESKD
group (stage 5)
not
undertaking
dialysis.
eGFR: 5.33
(4.31–7.72);
Age: 55.5 yrs
(48.25-64.5),
50% male.
Ethnicity not
explicitly
reported.

Demographics
of patients

Collection
and storage
not reported.

Stored at
-80°C

Stool
collection,
temp. &
storage

None taken
in prior 3
months.

Antibiotic
use

Not reported

reported.

Medications

Microbiota
analysis
technique

Not reported 16S ribosomal
RNA gene
sequencing
(V3 region)
Ion Personal
Genome
Machine system

Taxonomy
database

Dietary assessment

↓ α-diversity in RT and Not reported
HD vs. controls (Chao1
index p<0.001).
β-diversity reported
being different
between groups
(PERMANOVA based on
Bray-Curtis metric, p<
0.01)

plot presented data
based on weighted
and unweighted
UniFrac metrics,
ANOSIM test, p-value
not reported)

Diversity metrics

Legend: ESKD End-stage kidney disease, HD Haemodialysis, HC Healthy controls, PD Peritoneal dialysis, KS Kidney stones, KT Kidney transplant, DN Diabetic nephropathy, OTU Operational Taxonomic Units, Wt Weight,
Ht Height, WC Waist circumference, KSD Kidney stone disease, T2DM Type 2 diabetes mellitus, PPI Protein pump inhibitors, ESA Erythropoiesis-stimulating agents, ACEi Angiotensin-converting-enzyme inhibitors, ARBs
Angiotensin II receptor blockers, OHA Oral hypoglycaemic agents, eGFR Estimated glomerular filtration rate (ml/min/1.73m2), GFR Glomerular filtration rate (ml/min), vs. versus; ↓= decreased, ↑= increased

Guirong
2018 [46]

Reference

Table 2 Characteristics of included studies (Continued)
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Table 3 Quality assessment of included articles (n = 25)
Reference

Sampling (4 points)

Confounders controlled (2 points)

Exposure (3 points)

Total rating (9 points)

[37]

–−−−

–−

++−

2

[60]

–−−−

+−

++−

3

[44, 46]

+− − −

–−

+++

4

[41]

–−−−

+−

+++

4

[36, 48]

+− − −

+−

+++

5

[55]

+ +−−

–−

+++

5

[45]

+−−+

– −

+++

5

[38, 39, 47, 51]

+− − −

++

+++

6

[42]

+ +−−

+−

+++

6

[43, 53, 56, 57, 58, 61]

+ +−−

++

+++

7

[40, 49, 52, 62]

+−−+

++

+++

7

[50]

+++−

++

+++

8

Legend: ‘+’ Quality criterion satisfied; ‘-’ Quality criterion not satisfied or insufficient information to adjudicate as satisfied. Studies with a quality score of seven or
above were considered high-quality

significantly reduced in adults with kidney disease or kidney
stones relative to controls, among which seven papers reported a statistically signficant p-value [39, 46, 50, 52, 56,
57, 62]. Interestingly, the remaining three studies observed
a significant increase in α-diversity (observed species/
OTUs) in individuals with ESKD, DN and those undergoing HD therapy compared to controls [40, 44, 55].
Beta (β) diversity, a measure of the diversity that represents the similarity or difference in microbial composition
between sites or different samples [54], was evaluated in
12 studies (using Bray-Curtis, weighted and unweighted
UniFrac distance metrics). Ten studies reported compositional differences in the overall microbial communities
between controls and kidney disease or kidney stone cohorts, of which six studies [40, 46, 50, 52, 56, 57] reported
a statistically significant p-value (Table 2).
Altered microbial composition

Alterations of the microbial composition were presented
into two larger groups: adults with kidney disease and adults
with kidney stones. To highlight alterations of the microbial
composition specific to individuals receiving dialysis treatment, data from relevant articles that included adults undertaking HD or PD therapy are presented as a sub-analysis.
Microbiota profile of adults with kidney disease compared
to controls

Figure 2 characterises the differences in the gut microbiota
profile of individuals with kidney disease compared to controls. Based on strong level of evidence criteria, 20 microbial taxa were reported as being differentially abundant. For
instance, adults with kidney disease had relatively increased
abundances of Proteobacteria, Enterobacteriaceae, Streptococcaceae, Streptococcus and decreased abundances of
Firmicutes, Prevotellaceae, Prevotella, and Prevotella 9.

Based on the moderate evidence criteria, nine other taxa
were less abundant in comparison to controls including
Alcaligenaceae, Roseburia, Faecalibacterium and Faecalibacterium prausnitzii. In contrast, Bilophila, Desulfovibrio,
Klebsiella, Escherichia-Shigella, along with four other taxa
were more highly abundant (Fig. 2).
The population of an additional 112 microbial taxa
were altered, but this was based on weak evidence (data
not shown; Table S1, Additional file 1). Of these, 53 taxa
were more abundant in individuals with kidney disease,
while the remaining 59 were less abundant when compared to controls.
Microbiota profile of adults receiving dialysis therapy
Data from the six articles included in this sub-analysis
identified that five microbial taxa including Alphaproteobacteria, Streptococcaceae, and Streptococcus were
more abundant in adults receiving dialysis than controls
based on strong evidence criteria (Fig. 3). Based on moderate evidence criteria, the abundance of Bacteroidetes
was reduced, while Enterobacteriaceae was higher in
adults undergoing dialysis therapy. Results from two
other studies [46, 60] were not included in this subanalysis because it was unclear if the CKD cohort were
receiving haemodialysis at the time of sample collection
[46], and whether the results of individuals undertaking
dialysis therapy were statistically significant compared to
controls [60].
Stadlbauer et al. [57] investigated differences in the microbial profile according to dialysis type. Compared to
controls, adults receiving PD had reduced abundances of
Comamonadaceae and Campylobacteraceae and increased abundances of Ruminococcaceae and Corpococcus.
In HD participants, microbial families Comamonadaceae
and Campylobacteraceae were reportedly enriched, while
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Fig. 2 Altered taxa based on strong and moderate level of evidence for adults with kidney disease compared to controls. Figure includes data
from studies that investigated adults with CKD, IgAN, DN, ESKD, KT recipients and individuals receiving dialysis therapy (HD and PD)

Fig. 3 Sub-sample analysis of altered taxa based on strong and moderate level of evidence for adults with kidney disease receiving dialysis
therapy compared to controls. Figure includes data only from the studies that investigated adults receiving HD or PD therapy
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Fig. 4 Altered taxa based on strong and moderate level of evidence for adults with kidney stones compared to controls

Faecalibacterium prausnitzii, Roseburia intestinalis and
Clostridium nexile were depleted compared to controls.
Microbiota profile of kidney transplant recipients
One study in this review [46] included a sub-set of adults
who received a KT (n = 16) within the prior month of
study commencement. Their findings revealed that 54
taxa were altered compared to controls: Firmicutes, Faecalibacterium, Prevotella and three other bacterial members
were less abundance, while Bacteroidetes, Proteobacteria,
Alphaproteobacteria, Streptococcaceae, Streptococcus
along with 43 other taxa were enriched in individuals who
received a KT (data not shown; Table S1, Additional file 1).
Authors reported that based on the abundance of major
phyla, the overall gut microbial structure of KT recipients
was more similar to the participants with CKD (stages 3–4)
rather than the controls [46]. However, several microbial
taxa were unique to KT recipients. For example, Proteobacteria and Enterobacteriaceae were more highly abundant in
KT recipients in comparison to the CKD cohort.
Microbiota profile of adults with kidney stones compared to
controls

Based on strong evidence criteria, seven taxa were observed to be altered in adults with kidney stones. Within
the phylum Firmicutes, Lachnospiraceae NK4A136 group,
Ruminiclostridium 5 group, Dorea, Christensenellaceae, its
genus Christensenellaceae R7 group, as well as Enterobacter (from the Proteobacteria phylum) were all significantly
reduced compared to controls (Fig. 4). In contrast, Bacteroides was more highly abundant in adults with kidney
stones. Finally, the abundance of two other taxa, Bifidobacterium and Faecalibacterium were found to be significantly reduced based on moderate evidence criteria in
adults with kidney stones (Fig. 4).

The population of an additional 85 microbial taxa
were altered in kidney stone populations compared
to controls, but this was based on weak evidence
(data not shown; Table S2, Additional file 1), of
which 32 microbes increased and 53 taxa decreased.
Presence and absence data of archaea, microeukaryotes and fungi from Survyanshi et al. [37] were not
included as it was unclear if results were statistically
significant. Given this was the only paper that
employed a high-throughput approach to examine
different microbial community members (other than
bacteria), it seemed relevant to summarise their findings in the manuscript's supplementary information
(Table S3, Additional file 1).
Microbial markers for the potential detection of kidney
disease and kidney stones

Six studies reported values of the area under the receiver
operating characteristic (ROC) curve (AUC), ranging
between 0 and 1 [59]. The higher AUC value, the better
the test or model is at distinguishing between participants with disease and no disease [59]. Findings amongst
these studies were inconclusive.
Li et al. [52] identified Akkermansia (AUC = 0.753) and
Lactobacillus (AUC = 0.792) was able to differentiate between adults with CKD and controls, while the combination of both genera achieved the best result (AUC =
0.830). Lun et al. [60] reported that Lachnospira (AUC =
0.813) performed best for controls, while Ruminococcus
gnavus (AUC = 0.764) was best to detect adults with CKD.
In another study [46], the presence of 4 genera from the
bacterial family Lachnospiraceae (Shuttleworthia, Pseudobutyrivibrio, Roseburia and Lachnospira) were able to
identify adults with CKD from controls with high accuracy
(AUC = 0.92). The model by Tao et al. [40], which included Escherichia Shigella and Prevotella 9, had an
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AUC = 0.86 for predicting DN in their study population.
In adults with kidney stones, Tavasoli et al. [49] reported
that none of the bacteria examined in their study was able
to generate an acceptable AUC to differentiate from controls, while Tang et al. [53] reported that Pseudomonas
aeruginosa and Escherichia coli could be used to classify
their nephrolithiasis patients accurately (AUC = 0.947 and
AUC = 0.840, respectively).
Altered genetic functions of the microbiota

Among nine studies, eight [37, 38, 40, 46, 50, 52, 56, 57]
reported that the real or predicted functional capacity of
the gut microbiota in adults with kidney disease and kidney stones were substantially different from controls. Only
one of these study [50] undertook shotgun sequencing in
a subset of their study population (n = 10 participants) to
investigate the real functional potential of the microbial
communities for known metabolic pathways. Functional
gene-targeted amplicon sequencing was also employed by
another research group [37, 38]. However, the majority of
studies predicted the functional capacity of the gut microbiota using the bioinformatic software platform PICRUSt
(Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) [38, 40, 46, 52, 53, 56, 57].
In adults with stage 4–5 CKD, using PICRUSt, functional
genes relating to trimethylamine (TMA) metabolism were
increased (K07811, K07821, and K03532), while functional
genes relevant to choline, betaine and L-carnitine metabolism (K07271, K01004, K00499, K00130 and K00540) were
found to be significantly reduced compared to controls
[56]. In another study investigating adults with CKD, microbial genes associated with the circulatory system function were predicted to be significantly enriched, while
polyketide metabolism, as well as cell motility and secretion, was reduced relative to controls [52]. Similarly, Guirong et al. [46] also found that predicted microbial genes
relevant to polyketides metabolism were also significantly
reduced in adults with CKD and KT recipients along with
genetic information processing (involving the ribosome,
homologous recombination, and aminoacyl-tRNA), metabolism of co-factors, vitamins, nucleotides, terpenoids and
cellular processes including pyrimidine metabolism. Compared to controls, KT recipients and adults with CKD had
significantly greater predicted microbial genes associated
with the metabolism of carbohydrates, other amino acids,
and xenobiotics [46]. Differentially abundant bacterial functions related to lipid metabolism were reported between
DN, T2DM controls and controls [40]. In adults undergoing dialysis (HD or PD), four functional pathways relevant
to the renin-angiotensin system, glycosphingolipid biosynthesis, isoflavonoid biosynthesis and vasopressin regulated
water reabsorption were different compared to controls
[57]. However, the authors [57] did not report if these
functional pathways were upregulated or downregulated.
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In adults with kidney stones, shotgun sequencing analysis found that functional genes involved in oxalate degradation, such as formyl-CoA transferase and oxalyl-CoA
decarboxylase, were significantly reduced compared to
controls [50]. The highest representation of these genes
was detected in some Archaea and Bacteria, either with
known (Oxalobacter formigenes) or previously unknown
oxalate-degrading properties (Escherichia coli, Eggerthella
spp., Roseburia hominis, Bacteroides massiliensis, Clostridium citroniae) [50]. Through the application of DGGE fingerprinting and targeted-gene sequencing of the frc-gene,
Suryavanshi et al. [38] also confirmed that in addition to
Oxalobacter formigenes, several gut inhabitants possessed
the ability to metabolise oxalate. However, Suryavanshi
et al. [38] findings using PICRUSt completely contrasted
the shotgun sequencing results [50], as several genes involved in oxalate degradation were reported to be
enriched rather than depleted in their kidney stone cohort
[38]: formate dehydrogenase (K08349), oxalate/formate
antiporter (K08177), formyl-CoA transferase (K07749),
oxalyl-CoA decarboxylase (K01577) and oxalate decarboxylase (K01569). Tang et al. [53], who also investigated
these same metabolic pathways relevant to oxalate degradation, reported observing no significant difference between
groups. Other predicted functional activities of the gut
microbiota relating to energy metabolism, glycan synthesis, metabolism of co-factors and vitamins were downregulated, while lipid metabolism, carbohydrate metabolism and xenobiotic degradation metabolism were upregulated in adults with kidney stones [38]. In more recent
work [37], through targeted-gene sequencing of the bukgene, numerous butyrate-producing bacterial species that
were present in controls, were not found in samples from
participants with kidney stones.
Wong et al. [36] employed a different approach to the
above methods. This research group adopted a targeted
approach using the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database as well as a literature review
to search for corresponding functional genes of interest
alongside the list of bacterial families that differed in
relative abundance between adults receiving HD and
controls [36]. In individuals undertaking HD therapy, 12
of the 19 microbial families that were of highest abundance were urease-possessing families, while an additional five families reportedly possessed the uricase gene
(Cellulomonadaceae, Dermabacteraceaea, Micrococcaceae, Polyangiaceae, Xanthomonadaceae). Three bacterial families were believed to contain the tryptophanase
gene (Clostridiaceae, Enterobacteriaceae, and Verrucomicrobiaceae) and four were suspected to be capable of
deaminating tyrosine into p-Cresol, a precursor of pCS.
Furthermore, two of three bacterial families (Lactobacillaceae and Prevotellaceae) that were less abundant in
adults receiving HD have reported butyrate-producing

Stanford et al. BMC Nephrology

(2020) 21:215

functions, including members that possess phosphotransbutyrylase and butyrate kinase genes.
Dietary intake assessment and methodologies

Three of the 25 articles (12%) presented dietary intake results, of which two considered diet in their analysis [50, 61].
The authors concluded that dietary factors did not seem to
be involved in kidney disease− or nephrolithiasis−associated abnormalities of the gut microbial composition.
Of the three papers, two used the 131-item European
Prospective Investigation of Cancer and Nutrition (EPIC)
Food Frequency Questionnaire (FFQ) [50, 61], one of which
employed a trained research nutritionist to administer the
FFQ [50]. Barrios et al. [61] generated dietary scores from
the FFQ results through principal component analysis [61].
These dietary scores were then considered as covariates in
their analysis of the gut microbiota. In the second study,
Ticinesi et al. [50] assessed total energy (kcal), macronutrient (protein, carbohydrates, fats in grams), dietary fibre
(grams), alcohol (grams) and micronutrient consumption
(grams) between groups (adults with kidney stones and
controls). Only dietary calcium intake, along with other outcomes such as BMI, age, the sex were adjusted as covariates
in microbiota analyses [50]. The third study presented
macronutrient percentage consumption of total energy intakes for carbohydrates, proteins and fats between groups,
but details relaying the methods used for data collection, or
if the dietary data were considered in the analysis, were
missing [42]. Other papers included in this review did not
present results or assess actual dietary intakes. For instance,
authors simply reported that their cohort groups had similar eating habits [40, 62], or noted which participants were
self-reported vegetarians [38]. Other articles stated their
participants had received dietary restrictions without detailing the specific nutrition prescription, nor the counselling
and compliance approaches used [48].

Discussion
To the best of our knowledge, this is the first systematic review to quantitatively summarise the composition of the
gut microbiota profile in adults with kidney disease or kidney stones compared to controls. There is consistent evidence that the gut microbial composition is altered in
specific ways in adults with kidney disease and kidney
stones. However, more research in this area is required to
establish the specific role that these microbes have in kidney disease physiology and importantly, the clinical relevance in disease management. To further elucidate this,
studies should employ more sophisticated microbial characterisation techniques appropriate for functional annotation (for instance shotgun sequencing) with the integration
of other multi-omic technology such as metabolomics, as
well as investigate the gut microbiota in larger sample sizes
and different kidney disease populations. The findings from
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this review also highlighted a significant gap in the current
evidence-base regarding a lack of reporting to control for
the potential confounding effects of dietary intakes.
Lower bacterial diversity has been observed in a range of
other clinical conditions, including inflammatory bowel
disease (IBD), obesity, type 1 and 2 diabetes and coeliac
disease [63, 64]. However, differences in the diversity of microbial communities between cohorts with kidney disease
and kidney stones compared to controls remained inconclusive in this review. The overall dissimilarity in the microbial community structure as evaluated via β-diversity
distance metrics was statistically significant in six studies.
However, conflicting results were found for α-diversity
measures. Seven studies provided evidence that α-diversity
significantly reduced in adults with kidney disease or kidney stones relative to controls. In contrast, three studies reported an increase in microbial richness in adults with
CKD, two of which investigated adults with ESKD [44, 55],
including those receiving haemodialysis therapy [55]. It
was inferred that the increase of microbial richness might
reflect the proliferation of certain bacterial species [44, 55].
The overgrowth of microbes with pathogenic potential
(pathobiont) has been observed along with increases in intestinal concentrations of uraemic toxins [65] associated
with the progression of kidney disease, leading to the loss
and breach in the intestinal epithelial barrier [65]. Dialysis
is believed to worsen this epithelial barrier injury caused by
CKD [66], partly due to intra-dialysis or post-dialysis
hypotension bowel ischemia, and bowel oedema attributable to intra-dialysis fluid retention. Shi et al. [55] detected
bacterial DNA in plasma samples of 27% of participants
undergoing haemodialysis and 20% of their pre-dialysis
CKD subjects. Interestingly, most of the bacterial DNA
found in ESRD patients' blood was also found in their stool
samples, but not in the dialysate solutions [55]. The researchers proposed that the bloodstream bacteria was primarily derived from the dysbiotic intestinal microbiota,
and that HD exacerbates micro-inflammation in these patients to some degree by encouraging intestinal microbiota
translocation due to an impaired intestinal barrier [55].
Changes at the phylum level with the elevation of Proteobacteria and decrease of Firmicutes was found in kidney disease cohorts. Previous studies have reported this
enrichment of Proteobacteria is indicative of an unstable
microbial structure [67] and has been correlated to diseases of inflammatory phenotype [67] such as cardiovascular disease and IBD [68]. Lipopolysaccharides (LPS)
constitute the outer membranes of most Gram-negative
bacteria [69], and bacterial members of Proteobacteria
have been reported as potent LPS producers [70]. A connection between low-grade inflammation, sustained by
LPS, and the development of metabolic disorders is well
established, including evidence that indicates subclinical
endotoxemia is a potential cause for inflammation in
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individuals with CKD [65]. A mechanistic exploration in
male C57BL/6 mice showed that endotoxemia resulted in
the activation of mTOR signalling in macrophages, leading to progressive kidney inflammatory injuries and subsequent fibrosis [71]. Several other taxa that were reportedly
altered in adults with kidney disease have been linked to
various clinical outcomes. For instance, Streptococcus,
along with Klebsiella that was more abundant in kidney
disease populations, has been positively associated with
serum uraemic toxin TMAO levels [42]. Similarly, Streptococcus and Blautia were found to be related to other uraemic toxins such as IS and pCS and inversely associated
with kidney function (eGFR) [62]. On the other hand,
known commensal bacteria [9, 72] such Prevotella, Roseburia [51] and Fecalibacterium prausnitzii [47] that were
depleted among kidney disease populations, were associated with a better kidney function (eGFR) [47, 51] and decreases in Cystatin C levels [51]. Similarly, Prevotella,
Prevotella 2, Prevotella 9 and Megamonas were also associated with lower serum levels of IS and pCS [62], blood
urea nitrogen (BUN) and creatinine [46, 62].
Findings related to the predicted biological functions of the microbial community in adults with kidney disease supports the notion that the gut
microbiome may play an essential role in the production of ammonia from urea, and formation of uraemic
toxin TMAO via the reduced decomposition of its
precursor TMA. Genes relevant to choline, betaine,
and L-carnitine metabolism were found to be downregulated [56], possibly resulting in the production of
redundant TMA in the intestinal tract. In addition,
the predicted expression of genes related to trimethylamine (TMA) metabolism were increased in adults
with CKD [56]. Moreover, the majority of microbial
families that were enriched in a cohort of participants
receiving HD possessed the urease gene, while other
highly abundant microbial families possessed the uricase gene, tryptophanase gene and p-cresol forming
enzymes [36]. A reduction in bacterial families that
possess the butyrate-kinase gene and phosphotransbutyrylase needed to produce butyrate, a four-carbon
SCFA [36] was also identified among adults receiving
HD therapy. The capacity to produce SCFAs is critical physiologically as they are needed to provide the
energy for the growth and proliferation of colonocytes
[73]; protection of the colonic epithelium from
damage by reactive oxygen species and immunemodulating prostaglandins [73]; and aid in processes
that reduce luminal pH associated with the inhibition
of pathogenic microorganisms [74]. Interestingly, microbial genes essential to polyketide metabolism were
also predicted to be significantly reduced in adults
with CKD. Polyketides are a functionally diverse
family of bioactive natural products and have many
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important uses for human health [75, 76]. For example, polyketides that are widely used include antibacterials (erythromycin), antifungals (amphotericin),
anti-cancer agents (doxorubicin), immunosuppressants
(rapamycin) and cholesterol-lowering agents [76].
Adults with kidney stones also had a unique gut microbiota profile compared to controls. For instance, Bacteroides were consistently reported to be in increased
abundance, while Dorea, Enterobacter, Christensenellaceae, and its genus Christensenellaceae R7 group, decreased in adults with kidney stones. Discrepancies existed
across studies concerning the up-regulation or downregulation of microbial genes involved in oxalate degradation. Although in a small sample of kidney stone participants, shotgun sequencing analysis did indicate that the
expression of genes involved in oxalate degradation were
significantly reduced [50]. However, findings across included studies did agree that several microbes possessed
functional oxalate-degrading properties, challenging the
concept that the gut-nephrolithiasis-axis is merely limited
to Oxalobacter formigenes [38, 50]. Other predicted functional activities of the gut microbiota involved in energy
metabolism, glycan synthesis, lipid and carbohydrate metabolism were also altered compared to controls [38].
It is important to remark that predicting functional profiles through amplicon-based metagenomics (i.e. 16S
rRNA sequencing), which was the most common approach employed by studies, offers only a limited resolution of the microbial communities’ functional potential
and does not substitute shotgun sequencing [4]. However,
the findings of both kidney disease and kidney stone populations uncovered through amplicon-based metagenomics do provide valuable functional insights for future
research to undertake more in-depth explorations through
shotgun metagenomics, metatranscriptomics and metaproteomics needed to further our understandings.
Overall, the application of other multi-omic technologies in gut microbiota-related investigations of adults with
kidney disease or kidney stones was uncommon among
the included studies. Although, some research groups did
report results of their metabolomic analyses [39, 42, 56,
61, 62], a technique that involves identifying a set of metabolites within a sample [77]. For instance, De Angelis
et al. [39] observed differences in faecal and urinary metabolome composition between IgAN patients and controls. The authors suggested that elevated serum-free
amino acids detected in IgAN participants were possibly
associated with lower absorption of gastrointestinal proteins, resulting in increased levels of faecal p-cresol
due to enhanced microbial proteolytic metabolism
and changes in the microbiota [39]. In a separately
published paper with the same cohort already included in this review, Tao et al. [40] found that
when using an untargeted metabolomics approach,
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individuals with DN could be distinguished from age
and gender-matched diabetic controls by serum Larginine (AUC = 0.824) and taurine (AUC = 0.789) levels.
Nevertheless, greater employment of multi-omic technologies such as metabolomics needs to be integrated with
comprehensive data on the functional capability of the
microbiome and dietary intake in order to uncover some
of the most challenging questions concerning the prevention and management of CKD and kidney disorders.
Modulation of the microbiome provides a new potential therapeutic target for preventing or personalising
treatment in kidney disease and disorders. Despite hypotheses that postulate deleterious effects of specific diets and nutrients on the gastrointestinal microbiota
regarding uraemic toxin generation in kidney disease
[12, 26, 28, 78] and kidney stone formation [79], few explored this. Only three studies considered diet in their
study design [42, 50, 61], of which only two provided adequate details of the dietary assessment methods used
and considered diet as co-variates in the analysis of the
microbiota. Further limitations within these studies
existed. For instance, Barrios et al. [61] noted that information relating to dietary assessment and antibiotic use
was only available for 11% of their sample, making interpretations of their results difficult. To date, the majority
of the published studies have focused mainly on the effect of nutritional supplements such as prebiotics and
probiotics to improve gut health and symptoms in individuals with CKD or kidney stones. Unfortunately, these
types of therapies add further to the pill burden for this
patient group [80] and have produced inconsistent results in either case [81–84]. Clinical trials that explore
the effects of dietary components, such as dietary fibre
in other clinical conditions are emerging [85]. Nevertheless, few studies have examined the effect of dietary patterns on the gut microbiome in CKD or kidney stones.
Because nutrients are not consumed in isolation [86],
exploring the impact of whole foods and overall dietary
patterns on the gut microbiota may offer a superior and
rigorous methodological approach.
Further research into the lifestyle and environmental exposures that differ across the spectrum of kidney disease
conditions, and whether certain factors individually have a
more significant impact, or whether there is a unifying effect on the microbiome, is essential to advance this area of
research. For instance, along with subsequent dietary restrictions, other drug therapies and the dialysis procedure
itself may explain variations observed between dialysis and
non-dialysis CKD, but also between adults receiving PD
compared to HD [1, 57]. For example, the clearance of
metabolic wastes that may influence the microbiome differs as HD therapy is discontinuous, while PD works continuously [1]. Maio et al. [45] noted that there were
significant differences in 58 bacterial taxa, seven of which
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decreased over 12 weeks following the use of phosphate
binders (lanthanum carbonate). Hence, the impact of nonantibiotic drugs unique to people with CKD requires further exploration.
Our study has several limitations. Overall, the evaluation of results relating to alterations in the gut microbiota was challenging to evaluate mainly due to
heterogeneity of the inclusion criteria of individuals recruited, methodologies used and reporting of results. It
was thus not possible to conduct a meta-analysis. The
majority of cited studies had small sample sizes and
background information relating to the classification of
controls, diet, comorbidities, medications and other lifestyle factors (such as smoking status, alcohol consumption and physical activity) were poorly accounted for—
all of which may have influenced the results. The
strength of this review is reflected in its systematic approach to highlight the existing state of evidence in the
area of gut microbiota, kidney disease and kidney stone
disease. It serves to unify methods and study designs
needed to produce complementary findings and progress
in this field of research.

Conclusion
The gut microbiota profile of adults with kidney disease
and kidney stones was consistently reported to be substantially different from controls. Evidence for altered
genetic functions of the gut microbiota suggests a potential role of the gut microbiota in modulating host metabolism, particularly in the context of uraemic toxin
generation in adults with kidney disease—Although
greater investigation is still required. Studies with high
statistical power, comparable and reproducible methods
that include validated dietary assessment, as well as the
combined utilisation of more sophisticated multi-omic
technologies, are required to map functional capabilities
and more clearly elucidate the role of the microbiota in
kidney health.
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